October 2024
|
Breast cancer statistics 2024
Giaquinto A…Siegel R CA (ACS) ✅Take Home Breast cancer incidence is rising, particularly among younger women and Asian American/Pacific Islander women, while overall mortality has declined, though significant racial and ethnic disparities in survival persist, especially for Black and American Indian/Alaska Native women. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21863 45 |
|
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2
Phillips KA…Aeilts A JCO (ASCO) ✅Take Home Hormonal contraceptive use increases breast cancer risk in BRCA1 mutation carriers, particularly with long-term use, but shows no significant risk increase for BRCA2 mutation carriers. https://ascopubs.org/doi/10.1200/JCO.24.00176 |
|
FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
On October 10, 2024, the FDA granted approval for inavolisib in combination with palbociclib and fulvestrant for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer that is PIK3CA-mutated and resistant to endocrine therapy, following recurrence after adjuvant endocrine treatment; the approval also includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify eligible patients. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive 24 |
|
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer
Huppert L…Rugo H CA (ACS) ✅Take Home HR-positive, HER2-negative breast cancer, treated primarily with endocrine therapy and sometimes chemotherapy, is seeing improved outcomes through the addition of cyclin-dependent kinase inhibitors and emerging therapies like novel endocrine agents and antibody-drug conjugates, making treatment optimization crucial. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21777 79 |
|
HERA Trial Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer (HISTORICAL ARTICLE)
Piccart-Gebhart M….Gianni L (HERA Trial Study Team) NEJM/Published October 20, 2005 ✅Take Home The HERA trial demonstrated that one year of trastuzumab treatment significantly improves disease-free survival in women with HER2-positive breast cancer after chemotherapy, with minimal severe cardiotoxicity observed. https://www.nejm.org/doi/full/10.1056/NEJMoa052306 |
|
Dose constraints in breast cancer radiotherapy. A critical review
De Rose F…Meduri B Green Journal (ESTRO) ✅Take Home This review examines the impact of advanced radiotherapy techniques and hypofractionated schedules in breast cancer treatment, emphasizing the need to adapt dose-volume constraints for organs-at-risk to improve outcomes in long-term survivors. https://www.sciencedirect.com/science/article/abs/pii/S0167814024035692 22 |
|
Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE)
Brunet J….Bland K Cancer (ACS) ✅Take Home The ACTIVATE trial found that while aerobic exercise during chemotherapy for breast cancer did not significantly improve objective cognitive function, it notably enhanced self-reported cognitive function and quality of life among participants. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35540 23 |
|
Multidisciplinary Management of Pregnancy-Associated Breast Cancer
Roesch E…Valente S JCO OP (ASCO) ✅Take Home Pregnancy-associated breast cancer (PABC) is a rare but significant malignancy in pregnant women, requiring a multidisciplinary management approach that prioritizes the health and safety of both mother and fetus while addressing unique challenges related to diagnosis, treatment timing, and post-delivery care. https://ascopubs.org/doi/abs/10.1200/OP-24-00453 |
|
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Huppert L.A….Rugo H Annals of Oncology (ESMO) ✅Take Home This study found that specific clinical and molecular biomarkers, such as MP-High2, BP-Basal-type, and ImPrint positive, were associated with higher pathologic complete response rates and poorer distant recurrence-free survival in patients with hormone receptor-positive, HER2-negative early-stage breast cancer. https://www.annalsofoncology.org/article/S0923-7534(24)04070-5/abstract |
|
The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies
Kaidar-Person O…Poortmans P Green Journal (ESTRO) ✅Take Home The EORTC 22922/10925 trial found that elective internal mammary and medial supraclavicular radiation therapy significantly improved disease-free survival and reduced regional recurrences in stage I–III breast cancer patients, while the type of systemic therapy influenced outcomes and the site of first events. https://www.sciencedirect.com/science/article/abs/pii/S0167814024035412 |